Your Article Summary
See Latest ArticlesPhase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator
British Journal of Haematology, 07/13/07
Harmatz, P., et al. – For iron chelation, weekly treatment with starch-conjugated deferoxamine (S-DFO), a high-molecular-weight iron chelator with prolonged vascular retention, has the potential to achieve iron balance in the poorly compliant patient.
Methods- IV infusion of S-DFO into groups of four transfusion-dependent patients with beta-thalassaemia at single doses of 150, 300, 600, 900 mg/kg
- Evaluation of urinary iron excretion and pharmacologic parameters for 1 week and of safety for 3 weeks
- No drug-related effects were observed on clinical chemistries, hematological and coagulation parameters, urinalyses, vital signs, or ECGs
- Drug-related adverse events were limited to four urticarial reactions, none requiring infusion termination
- The drug stimulated clinically significant urinary iron excretion; the 900-mg dose induced iron excretion of 1.31 mg/kg over 1 week with residual iron-biding capacity in plasma for >6 days
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Milnacipran: Beyond a Role of Antidepressant
Clinical Neuropharmacology, 12/14/09
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/14/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/14/09
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy
Cancer, 12/14/09
Travel-related thromboembolism: mechanisms and avoidance
Expert Review of Cardiovascular Therapy , 12/14/09
Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
Journal of the National Cancer Institute, 12/14/09